Abstract:Boue, F., Gabarre, J., Gisselbrecht, C., Reynes, J., Cheret, A., Bonnet, F., Billaud, E., Raphael, M., Lancar, R. & Costagliola, D. (2006) Phase II trial of CHOP plus rituximab in patients with HIVassociated non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 24, 4123–4128. Bower, M., Gazzard, B., Mandalia, S., NewsomDavis, T., Thirlwell, C., Dhillon, T., Young, A. M., Powles, T., Gaya, A., Nelson, M. & Stebbing, J. (2005) A Prognostic Index for Systemic AIDS-Related Non-Hodgkin Lymphoma Treated in the Era of Highly Active Antiretroviral Therapy. Annals of Internal Medicine, 143, 265–273. Crum-Cianflone, N., Hullsiek, K.H., Marconi, V., Weintrob, A., Ganesan, A., Barthel, R.V., Fraser, S., Agan, B.K. & Wegner, S. (2009) Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS, 23, 41–50. Kaplan, L.D., Lee, J.Y., Ambinder, R.F., Sparano, J. A., Cesarman, E., Chadburnm, A., Levine, A.M. & Scadden, D.T. (2005) Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood, 106, 1538–1543. Navarro, J.T., Lloveras, N., Ribera, J.M., Oriol, A., Mate, J.L. & Feliu, E. (2005) The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica, 90, 704–706. Patel, P., Hanson, D.L., Sullivan, P.S., Novak, R. M., Moorman, A.C., Tong, T.C., Holmberg, S. D. & Brooks, J.T. (2008) Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Annals of Internal Medicine, 148, 728–736. Ribera, J.M., Oriol, A., Morgades, M., GonzálezBarca, E., Miralles, P., López-Guillermo, A., Gardella, S., López, A., Abella, E. & Garcı́a, M. (2008) Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. British Journal of Haematology, 140, 411–419. Sparano, J.A., Lee, J.Y., Kaplan, L.D., Levine, A.M., Ramos, J.C., Ambinder, R.F., Wachsman, W., Aboulafia, D., Noy, A., Henry, D.H., von Roenn, J., Dezube, B.J., Remick, S.C., Shah, M.H., Leichman, L., Ratner, L., Cesarman, E., Chadburn, A. & Mitsuyasu, R. (2010) Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood, 115, 3008– 3016. Spina, M., Jaeger, U., Sparano, J.A., Talamini, R., Simonelli, C., Michieli, M., Rossi, G., Nigra, E., Berretta, M., Cattaneo, C., Rieger, A.C., Vaccher, E. & Tirelli, U. (2005) Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood, 105, 1891–1897. Wyen, C., Jensen, B., Hentrich, M., Siehl, J., Sabranski, M., Esser, S., Gillor, D., Müller, M., van Lunzen, J., Wolf, T., Bogner, J.R., Wasmuth, J. C., Christ, H., Fätkenheuer, G. & Hoffmann, C. (2011) Treatment of AIDS-related Lymphomas (ARL): rituximab is beneficial even in severely immunosuppressed patients. AIDS, Nov 22 E-pub ahead of print.

Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes

[Prediction of the Pharmacokinetic Drug-Drug Interaction of Pravastatin and Pitavastatin with Cyclosporine by a Digital Liver Model Based on Metabolism and Transporter].

Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions

Quantitative Analysis of Complex Drug-Drug Interactions between Cerivastatin and Metabolism/Transport Inhibitors Using Physiologically Based Pharmacokinetic Modeling

Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects

Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling.

Building a Predictive PBPK Model for Human OATP Substrates: a Strategic Framework for Early Evaluation of Clinical Pharmacokinetic Variations Using Pitavastatin as an Example

Prediction of the Impact of CYP2C19 Polymorphism on Drug-Drug Interaction Between Voriconazole and Tacrolimus Using Physiologically- Based Pharmacokinetic Modelling

Immune thrombocytopenia and anticoagulation: the role of romiplostim in the early treatment

A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug–Drug–Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine

A highly sensitive hybrid organic-inorganic sensor for continuous monitoring of hemoglobin.

Calibrating the In Vitro–In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models

My last will and testament on rapid elimination and ultimate global eradication of poliomyelitis and measles.

Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites As CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model

Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions Involving Inhibitory Metabolite: A Case Study of Amiodarone

Intravascular lymphomatosis with bone marrow involvement.

A theoretical study of closed polyacene structures.

Prediction of Drug-Drug Interaction Between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically-Based Pharmacokinetic Modelling.

Early Prediction and Impact Assessment of CYP3A4-Related Drug-Drug Interactions for Small-Molecule Anticancer Drugs Using Human-CYP3A4-Transgenic Mouse Models

Structure-property relationships and machine learning models for addressing CYP3A4-mediated victim drug-drug interaction risk in drug discovery.

Evaluation of Drug–Drug Interactions Between Clarithromycin and Direct Oral Anticoagulants Using Physiologically Based Pharmacokinetic Models